F113. LONG-TERM PHYSICAL HEALTH AND MORTALITY OUTCOMES OF PATIENTS WITH SCHIZOPHRENIA WITH CLOZAPINE AUGMENTATION WITH ANTI-PSYCHOTIC DRUGS

摘要

About a third of schizophrenia patients would not have sufficient clinical response to antipsychotic treatment. The only drug approved for this population is clozapine, yet worldwide reports suggest underuse of clozapine and significant delay in initiating treatment. Moreover, as a robust clinical response is evident in only about half of patients treated with clozapine, the common practice is to augment the compound with another antipsychotic compound. However, little is known about the nature of this augmentation and the outcome in real-world setting.